$300 Million is the total value of TRV GP III, LLC's 3 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VYGR | Sell | VOYAGER THERAPEUTICS, INC. | $154,194,000 | -12.6% | 7,891,176 | -16.0% | 51.35% | -19.2% |
| NTGN | New | NEON THERAPEUTICS, INC. | $122,745,000 | – | 9,741,636 | +100.0% | 40.88% | – |
| JNCE | JOUNCE THERAPEUTICS, INC. | $23,354,000 | -65.7% | 3,048,780 | 0.0% | 7.78% | -68.3% | |
| MYOK | Exit | MYOKARDIA, INC. | $0 | – | -680,272 | -100.0% | -11.95% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Mark Levin #1
- Kevin P. Starr #2
- Robert I. Tepper #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-07
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VOYAGER THERAPEUTICS, INC. | 22 | Q1 2023 | 74.0% |
| JOUNCE THERAPEUTICS, INC. | 20 | Q3 2022 | 24.5% |
| PLIANT THERAPEUTICS, INC. | 14 | Q3 2023 | 100.0% |
| FULCRUM THERAPEUTICS, INC. | 14 | Q4 2022 | 43.8% |
| REVOLUTION MEDICINES, INC. | 12 | Q4 2022 | 53.8% |
| DECIBEL THERAPEUTICS, INC. | 10 | Q2 2023 | 66.3% |
| NEON THERAPEUTICS, INC. | 8 | Q1 2020 | 41.1% |
| NURIX THERAPEUTICS, INC. | 8 | Q2 2022 | 17.7% |
| RELAY THERAPEUTICS, INC. | 2 | Q4 2020 | 37.7% |
| MYOKARDIA, INC. | 2 | Q1 2018 | 22.1% |
View TRV GP III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 4 | 2023-02-06 |
| 4 | 2023-02-01 |
| 4 | 2023-01-31 |
| 4 | 2023-01-26 |
| 4 | 2023-01-24 |
View TRV GP III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.